Mar 9, 2020   SOURCE: PR NewsWire

Outlook on the Attention Deficit Hyperactivity Disorder (ADHD) Market to 2026

DUBLIN, March 9, 2020 /PRNewswire/ -- The "Market Spotlight: Attention Deficit Hyperactivity Disorder (ADHD)?" report has been added to ResearchAndMarkets.com's offering.

http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

This Market Spotlight report covers the Attention Deficit Hyperactivity Disorder (ADHD) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

    --  The research estimates that in 2017, there were 177.3 million prevalent
        cases of attention deficit hyperactivity disorder (ADHD) in people aged
        5-44 years worldwide, and forecasts that number to increase to 187.4
        million prevalent cases by 2026.
    --  Approved drugs in the ADHD space target dopamine, dopamine reuptake,
        norepinephrine (noradrenaline), norepinephrine (noradrenaline)
        reuptake/transporter, and the alpha 2 adrenergic receptor. The vast
        majority of approved therapies are administered via the oral route.
    --  The highest proportion of industry-sponsored drugs in active clinical
        development for ADHD are in Phase II, with only one drug in the NDA/BLA
        stage.
    --  Therapies in development for ADHD focus on a wide variety of targets.
        All pipeline drugs for ADHD are administered via the oral route.
    --  High-impact upcoming events for drugs in the ADHD space comprise topline
        Phase I/II and Phase III trial results, pivotal efficacy study results,
        an expected patent expiration, an estimated PDUFA date, and a meeting
        with the FDA.
    --  The overall likelihood of approval of a Phase I ADHD asset is 12.3%, and
        the average probability a drug advances from Phase III is 75%. Drugs, on
        average, take 9.0 years from Phase I to approval, compared to 8.7 years
        in the overall psychiatry space.
    --  There have been 20 licensing and asset acquisition deals involving ADHD
        drugs during 2015-20. Impax Laboratories' acquisition of certain assets
        related to generic products from Teva and Allergan in 2016 for $586m was
        the largest deal.
    --  The distribution of clinical trials across Phase I-IV indicates that the
        majority of trials for ADHD have been in the late phases of development,
        with 53% in Phase III-IV, and 47% in Phase I-II.
    --  The US has a substantial lead in the number of ADHD clinical trials
        globally. Germany leads the major EU markets, while Japan has the top
        spot in Asia.
    --  Clinical trial activity in the ADHD space is dominated by completed
        trials. Takeda has the highest number of completed clinical trials for
        ADHD, with 158 trials.
    --  Takeda leads industry sponsors with the highest overall number of
        clinical trials for ADHD, followed by Eli Lilly.

Key Topics Covered:

1. OVERVIEW

2. KEY TAKEAWAYS

3. DISEASE BACKGROUND

    --  Subtypes

4. TREATMENT

    --  Non-pharmacological therapy
    --  Pharmacological therapy

5. EPIDEMIOLOGY

6. MARKETED DRUGS

7. PIPELINE DRUGS

8. RECENT EVENTS AND ANALYST OPINION

    --  SPN-810 for ADHD (December 9, 2019)
    --  SPN-810 for ADHD (November 5, 2019)
    --  Multiple Drugs for ADHD (September 04, 2019)
    --  Vafidemstat for ADHD (April 25, 2019)
    --  Monarch eTNS system for ADHD (April 19, 2019)
    --  SPN-812 for ADHD (March 28, 2019)
    --  AEVI-001 for ADHD (January 02, 2019)
    --  SPN-812 for ADHD (December 20, 2018)
    --  SPN-812 for ADHD (December 06, 2018)
    --  Dasotraline for ADHD (August 31, 2018)
    --  KP415 for ADHD (July 9, 2018)

9. KEY UPCOMING EVENTS

10. KEY REGULATORY EVENTS

    --  Supernus ADHD NDA Repurposes Old European Antidepressant
    --  NeuroSigma Monarch eTNS Becomes The First FDA-Cleared ADHD Device
    --  Approval of Vyvanse for Pediatric ADHD in Japan
    --  Adhansia XR Approval Boosts Purdue's Move Away From Opioids

11. PROBABILITY OF SUCCESS

12. LICENSING AND ASSET ACQUISITION DEALS

    --  Teijin Gains Japanese Rights To NeuroSigma's Monarch eTNS Device For
        ADHD
    --  KemPharm Offloads Two ADHD Candidates To Gurnet Point
    --  Shionogi Licenses Akili's Digital Medicine Candidates For ADHD, ASD

13. PARENT PATENTS

14. REVENUE OPPORTUNITY

15. CLINICAL TRIAL LANDSCAPE

    --  Sponsors by status
    --  Sponsors by phase
    --  Recent events

16. BIBLIOGRAPHY

    --  Prescription information

17. APPENDIX

Companies Mentioned 

    --  Allergan
    --  Eli Lilly
    --  Johnson & Johnson
    --  Takeda
    --  Teva
    --  Teijin
    --  NeuroSigma
    --  KemPharm
    --  Gurnet Point
    --  Shionogi
    --  Akili

For more information about this report visit https://www.researchandmarkets.com/r/1px7gg

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/outlook-on-the-attention-deficit-hyperactivity-disorder-adhd-market-to-2026-301019982.html

SOURCE Research and Markets